Eptifibatide beneficial in patients scheduled to undergo percutaneous coronary interventions

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1269, 2001-01, pp. : 21-21

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical outcomes are similar for abciximab and eptifibatide in patients who undergo percutaneous coronary intervention (PCI), but abciximab is associated with greater costs

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 493, 2005-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Clinical outcomes are similar for abciximab and eptifibatide in patients who undergo percutaneous coronary intervention (PCI), but abciximab is associated with greater costs

By  

Inpharma, Vol. 1, Iss. 1518, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Therapeutic Use of Intravenous Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention: Acute Coronary Syndromes and Elective Stenting

By Juan F. Granada   Neal S. Kleiman  

American Journal of Cardiovascular Drugs, Vol. 4, Iss. 1, 2004-01 ,pp. : 31-41

Adis International

Access to resources Recommend Favorite

Eptifibatide: A Review of its Use in Patients with Acute Coronary Syndromes and/or Undergoing Percutaneous Coronary Intervention

By Curran Monique P.   Keating Gillian M.  

Drugs, Vol. 65, Iss. 14, 2005-01 ,pp. : 2009-2035

Adis International

Access to resources Recommend Favorite

Eptifibatide: A Review of its Use in Patients with Acute Coronary Syndromes and/or Undergoing Percutaneous Coronary Intervention

By Goa K.L.   Noble S.  

Drugs, Vol. 57, Iss. 3, 1999-03 ,pp. : 439-462

Adis International

Access to resources Recommend Favorite